Vicapsys Life Sciences annual cash and equivalents
2019
2020
2021
2022
2023
Vicapsys Life Sciences Cash & Equivalents Growth & History (VICP)
Vicapsys Life Sciences's cash and equivalents was $9,422 for fiscal 2023.
View full Vicapsys Life Sciences company overviewVicapsys Life Sciences annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | $9,422 | −$4,675 | −33.16% |
| 2022 | 2022-12-31 | $14,097 | −$203,198 | −93.51% |
| 2021 | 2021-12-31 | $217,295 | $216,026 | +17023.33% |
| 2020 | 2020-12-31 | $1,269 | −$262,897 | −99.52% |
| 2019 | 2019-12-31 | $264,166 | — | — |
Vicapsys Life Sciences quarterly cash and equivalents
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q3 2024 | 2024-09-30 | $89,569 | $36,037 | +67.32% |
| Q4 2023 | 2023-12-31 | $9,422 | −$4,675 | −33.16% |
| Q3 2023 | 2023-09-30 | $53,532 | $27,322 | +104.24% |
| Q2 2023 | 2023-06-30 | $231,277 | $213,988 | +1237.71% |
| Q1 2023 | 2023-03-31 | $4,140 | −$97,179 | −95.91% |
| Q4 2022 | 2022-12-31 | $14,097 | −$203,198 | −93.51% |
| Q3 2022 | 2022-09-30 | $26,210 | −$139,339 | −84.17% |
| Q2 2022 | 2022-06-30 | $17,289 | −$153,335 | −89.87% |
| Q1 2022 | 2022-03-31 | $101,319 | $70,856 | +232.60% |
| Q4 2021 | 2021-12-31 | $217,295 | $216,026 | +17023.33% |
| Q3 2021 | 2021-09-30 | $165,549 | $163,895 | +9909.01% |
| Q2 2021 | 2021-06-30 | $170,624 | $165,638 | +3322.06% |
| Q1 2021 | 2021-03-31 | $30,463 | −$485 | −1.57% |
| Q4 2020 | 2020-12-31 | $1,269 | −$262,897 | −99.52% |
| Q3 2020 | 2020-09-30 | $1,654 | — | — |
| Q2 2020 | 2020-06-30 | $4,986 | — | — |
| Q1 2020 | 2020-03-31 | $30,948 | — | — |
| Q4 2019 | 2019-12-31 | $264,166 | — | — |
Vicapsys Life Sciences cash and equivalents trends
Between the periods ended 2019-12-31 and 2023-12-31, Vicapsys Life Sciences's cash and equivalents decreased from $264,166 to $9,422, a change of −$254,744. The latest reported quarter, Q3 2024, shows $89,569.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vicapsys Life Sciences source filings ↗